Jazz Pharmaceuticals JAZZ Equity Method Income
Equity Method Income at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromEquityMethodInvestments.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's equity method income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's equity method income?
- Jazz Pharmaceuticals (JAZZ) reported equity method income of $0 in Q1 2026.
- How has Jazz Pharmaceuticals's equity method income changed year-over-year?
- Jazz Pharmaceuticals's equity method income increased by 100.0% year-over-year, from -$500K to $0.
- What is the long-term trend for Jazz Pharmaceuticals's equity method income?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's equity method income has grown at a -0.9% compound annual growth rate (CAGR), from -$714K to -$690K.
- What does equity method income mean?
- The company's share of profits or losses from businesses it partially owns but does not fully control.
- How do you interpret equity method income?
- Positive income indicates successful performance of strategic partnerships, while losses may signal underperforming investments.
- How does equity method income compare across companies?
- Common for companies with significant joint ventures or minority stakes in other firms.